June 20 (UPI) -- Drugmaker Eli Lilly said Tuesday that it had agreed to a $2.4 billion deal to acquire Dice Therapeutics, a company that develops drugs for autoimmune diseases.
Eli Lilly will pay $48 per share in cash to buy the San-Francisco-based Dice. The transaction is expected to close in the third quarter of this year. Dice's stock price jumped 37% Tuesday morning.